MedTrace Logo

Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients

NCT04023760 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-05-03

No results posted yet for this study

Summary

This study aims to evaluate the pharmacokinetics (PK) of apixaban in kidney and lung transplant recipients stabilized on either cyclosporine or tacrolimus as part of their immunosuppressive therapy.

Conditions

  • Pharmacokinetics
  • Kidney Transplant
  • Lung Transplant

Interventions

DRUG

Apixaban

Study subjects given a single-dose of apixaban 10 mg.

Sponsors & Collaborators

  • Saskatchewan Health Research Foundation

    collaborator OTHER

  • Lung Association of Saskatchewan

    collaborator UNKNOWN

  • University of Saskatchewan

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-26
Primary Completion
2020-03-30
Completion
2020-03-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04023760 on ClinicalTrials.gov